Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Medical Device

Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment

Fineline Cube Apr 18, 2023

Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...

Company R&D

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

Fineline Cube Apr 17, 2023

German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...

Company Drug

Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study

Fineline Cube Apr 17, 2023

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...

Company Deals

Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech

Fineline Cube Apr 17, 2023

Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly...

Company Drug

Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)

Fineline Cube Apr 17, 2023

Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it...

Company Deals

Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development

Fineline Cube Apr 17, 2023

Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...

Company Deals

Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply

Fineline Cube Apr 17, 2023

Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...

Company Drug

CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine

Fineline Cube Apr 17, 2023

CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...

Company Drug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

Fineline Cube Apr 17, 2023

JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...

Company

Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 17, 2023

Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...

Company

Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang

Fineline Cube Apr 17, 2023

China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...

Policy / Regulatory

Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng

Fineline Cube Apr 17, 2023

The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...

Company Drug

Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial

Fineline Cube Apr 17, 2023

China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its...

Company Drug

AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery

Fineline Cube Apr 17, 2023

China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...

Medical Device Policy / Regulatory

NHC Proposes Updates to Access Standards for Class A and B Medical Equipment

Fineline Cube Apr 17, 2023

The National Healthcare Commission (NHC) has released two proposed updates to the Access Standards for...

Company Drug

Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023

Fineline Cube Apr 17, 2023

China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...

Company Drug

RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors

Fineline Cube Apr 14, 2023

RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from...

Company Drug

Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial

Fineline Cube Apr 14, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...

Company Deals

Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007

Fineline Cube Apr 14, 2023

Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...

Company Deals Digital

Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion

Fineline Cube Apr 14, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...

Posts pagination

1 … 589 590 591 … 718

Recent updates

  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
  • NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Company Deals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.